CT Imaging Findings after Stereotactic Radiotherapy for XXXX .

@entity1 @entity96 @entity409 @entity201 @entity3 @entity157
Purpose. To study radiological response to stereotactic radiotherapy for focal @entity96 . Materials and Methods. In this IRB-approved, HIPAA-compliant study CTs of 68 consecutive @entity1 who underwent stereotactic radiotherapy for @entity96 between 01/2006 and 01/2010 were retrospectively reviewed. Two independent reviewers evaluated lesion volume and enhancement pattern of the lesion and of juxtaposed liver parenchyma. Results. 36 subjects with @entity157 ( @entity157 ), 25 with liver @entity3 , and seven with @entity201 ( @entity201 ) were included in study. Mean follow-up time was 5.6    7.1 months for @entity157 , 6.4    5.1 months for @entity3 , and 10.1    4.8 months for the @entity201 . Complete response was seen in 4/36 (11.1%) HCCs and 1/25 (4%) @entity3 . Partial response (>30% decrease in long diameter) was seen in 25/36 (69%) HCCs, 14/25 (58%) @entity3 , and 7/7 (100%) of CCCs. Partial response followed by local recurrence (>20% increase in long diameter from nadir) occurred in 2/36 (6%) HCCs and 4/25 (17%) @entity3 . Liver parenchyma adjacent to the lesion demonstrated a prominent halo of delayed enhancement in 27/36 (78%) of HCCs, 19/21 (91%) of @entity3 , and 7/7 (100%) of CCCs. Conclusion. Sustainable radiological partial response to stereotactic radiotherapy is most frequent outcome seen in @entity409 . Prominent halo of delayed enhancement of the adjacent liver is frequent finding.
